Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study

Björn Pasternak,^{1,2} Malin Inghammar,^{2,3} Henrik Svanström²

¹Clinical Epidemiology Unit T2, Department of Medicine Solna, Karolinska Institutet, 17176 Stockholm, Sweden

²Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

³Section for Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden

Correspondence to: B Pasternak bjorn.pasternak@ki.se

Additional material is published online only. To view please visit the journal online.

Cite this as: *BMJ* 2018;360:k678 <http://dx.doi.org/10.1136/bmj.k678>

Accepted: 22 January 2018

ABSTRACT

OBJECTIVE

To investigate whether oral fluoroquinolone use is associated with an increased risk of aortic aneurysm or dissection.

DESIGN

Nationwide historical cohort study using linked register data on patient characteristics, filled prescriptions, and cases of aortic aneurysm or dissection.

SETTING

Sweden, July 2006 to December 2013.

PARTICIPANTS

360 088 treatment episodes of fluoroquinolone use (78% ciprofloxacin) and propensity score matched comparator episodes of amoxicillin use (n=360 088).

MAIN OUTCOME MEASURES

Cox regression was used to estimate hazard ratios for a first diagnosis of aortic aneurysm or dissection, defined as admission to hospital or emergency department for, or death due to, aortic aneurysm or dissection, within 60 days from start of treatment.

RESULTS

Within the 60 day risk period, the rate of aortic aneurysm or dissection was 1.2 cases per 1000 person years among fluoroquinolone users and 0.7 cases per 1000 person years among amoxicillin users. Fluoroquinolone use was associated with an increased risk of aortic aneurysm or dissection (hazard ratio 1.66 (95% confidence interval 1.12 to 2.46)), with an estimated absolute difference of 82 (95% confidence interval 15 to 181) cases of aortic aneurysm or dissection by 60 days per 1 million treatment episodes. In a secondary analysis, the hazard ratio for the association with fluoroquinolone use was 1.90 (1.22 to 2.96) for aortic aneurysm and 0.93 (0.38 to 2.29) for aortic dissection.

CONCLUSIONS

In a propensity score matched cohort, fluoroquinolone use was associated with an increased risk of aortic aneurysm or dissection. This association appeared to be largely driven by aortic aneurysm.

Introduction

Fluoroquinolones remain among the most commonly used antibiotics globally, and about 30 million outpatient prescriptions for fluoroquinolones are issued per year in the United States alone.^{1,2} Fluoroquinolone use is associated with an increased risk of tendon disorders, including Achilles tendon rupture and tendinopathy.^{3,4} The mechanisms behind these adverse events, which are recognised in a boxed warning, are thought to implicate non-antimicrobial properties of fluoroquinolones. These antibiotics have been shown to induce degradation of collagen and other structural components of the extracellular matrix by stimulating the activity of matrix metalloproteinases,^{5,6} reduce de novo production of collagen,⁷ and induce oxidative stress in tendon cells.⁸

Rupture and dissection of the aorta are life threatening medical emergencies that need prompt intervention, often involving surgery. The integrity of the human aorta heavily depends on an intact extracellular matrix, and the pathophysiology of aortic aneurysm is known to involve excessive tissue breakdown through matrix metalloproteinases.^{9,10} Two recent observational studies have raised concern that fluoroquinolone antibiotics could increase the risk of aortic aneurysm or dissection.^{11,12} Although limitations in study design have not resulted in firm conclusions, with both studies reporting more than a twofold increased risk of aortic aneurysm or dissection associated with fluoroquinolone exposure, these data have prompted the European Medicines Agency to initiate a safety assessment.¹³

We conducted a nationwide, register based cohort study in Sweden to investigate the risk of aortic aneurysm or dissection, comparing treatment episodes of fluoroquinolone use with episodes of amoxicillin use.

Methods

We conducted a cohort study based on linked nationwide data from Swedish registers, (July 2006 to December 2013). We investigated the risk of a first diagnosis of aortic aneurysm or dissection (admission to hospital or emergency department for aortic aneurysm or dissection, or death due to aortic aneurysm or dissection) associated with oral fluoroquinolone use, as compared with amoxicillin use, within a 60 day period from start of treatment. We used two major strategies to control for confounding.

WHAT IS ALREADY KNOWN ON THIS TOPIC

Recent studies have raised concern that fluoroquinolone antibiotics could be associated with an increased risk of aortic aneurysm. Fluoroquinolones have non-antimicrobial properties that might jeopardise the integrity of the extracellular matrix of the vascular wall.

WHAT THIS STUDY ADDS

In this nationwide, propensity score matched cohort study in Sweden, there was a 66% increased rate of aortic aneurysm or dissection associated with oral fluoroquinolone use, compared with amoxicillin use, within a 60 day risk period from start of treatment.

This result corresponded to an absolute difference of 82 cases of aortic aneurysm or dissection per 1 million treatment episodes; the association appeared to be largely driven by aortic aneurysm. Although the absolute risk increase was relatively small, it should be interpreted in the context of the widespread use of fluoroquinolones.

To account for potential confounding by indication (infection, or unmeasured factors associated with receipt of antibiotic treatment, might be associated with increased risk of aortic aneurysm or dissection), we used an active comparator design, with amoxicillin as the comparator. Amoxicillin is an antibiotic with no known association with aortic aneurysm or dissection, and its approved indications largely overlap with those of fluoroquinolones, including respiratory and urinary tract infections. To control for potential confounding from differences in baseline health status, we used a propensity score matched design, taking into account demographic characteristics, medical history, concomitant use of other medical drugs, and measures of healthcare use.

Sources of data

We used the following data sources:

- National Prescribed Drug Register, which captures all prescriptions filled at all Swedish pharmacies since July 2005, including details pertaining to the specific drug and the date the prescription was filled.¹⁴
- National Patient Register, which captures data for all hospital admissions and outpatient and emergency department visits in Sweden, including physician assigned diagnoses according to ICD-10 (international classification of diseases, 10th revision) as well as data for surgical procedures.¹⁵
- Statistics Sweden, which captures data for demographic characteristics.
- Swedish Cause of Death Register, which captures all causes of death in Sweden and is based on death certificates.

Cohort

The source population included all adults in Sweden who received a prescription for fluoroquinolones or amoxicillin during the study and who were aged 50 years or older. From this group, we identified treatment episodes of fluoroquinolone and amoxicillin use in individuals who:

- Had no previous diagnosis of aortic aneurysm or dissection (data available from 1997 onwards)
- Did not use study antibiotics in the previous 120 days
- Were not admitted to hospital in the previous 120 days (information on in-hospital antibiotic exposure was not available)
- Did not receive multiple antibiotics (any) on the same day
- Did not have a diagnosis indicating endstage illness or drug/alcohol misuse (web table 1)
- Had used at least one prescription drug in the past year (to ensure some degree of activity in the healthcare system).

Previous studies reporting associations between fluoroquinolones and aortic aneurysm or dissection used risk periods of approximately 37 and 60 days, respectively.^{11 12} Given these reports, our risk period of interest was defined as a 60 day period from start of

treatment (days 1 to 60, starting from the date when the prescription was filled). We also included a secondary analysis investigating the subsequent 60 days (days 61 to 120). To explore the timing of the association, the 60 day risk period was divided into 10 day intervals, assessing the number of events in each interval.

Propensity score

To control for potential confounders, treatment episodes of fluoroquinolone and amoxicillin use were matched in a 1:1 ratio on the basis of propensity scores using the 5->1 digit greedy matching algorithm.^{16 17} The propensity score for fluoroquinolone exposure was estimated by a logistic regression model, including 47 covariates as predictors, covering demographic information, medical history, prescription drug use, and healthcare use (web table 2). One covariate, region of residence, had missing values (0.1% missing); missing values were handled by inclusion of a missing value category.¹⁸ We assessed covariate balance in the matched cohort by checking standardised differences between the groups; we considered a covariate to be well balanced if the standardised difference was less than 10%.

Aortic aneurysm or dissection

The primary outcome was defined as a first diagnosis of aortic aneurysm or dissection, including thoracic, thoracoabdominal, and abdominal aneurysm (with or without rupture) and aortic dissection (ICD-10 codes in web table 3). In a secondary analysis, the outcomes of any aortic aneurysm and dissection, respectively, were analysed separately. The outcome was identified as the primary diagnosis (that is, the main diagnosis) associated with admission to hospital or emergency department (as captured through the National Patient Register) or as the underlying cause of death (as recorded in the Cause of Death Register). In a review of medical records of thoracic aortic aneurysms and aortic dissection identified through these two registers, 165 (97%) of 170 cases involved a confirmed diagnosis of any aortic aneurysm.¹⁹ In a validation study of the Danish National Patient Register, which is comparable in content and structure to its Swedish counterpart owing to similarities in organisation of the registers and healthcare systems, the positive predictive values for a register based strategy for capture of cases were 92% for aortic dissection and 100% for aortic aneurysm.²⁰

The outcome definition was designed to capture the first clinical encounter of aortic aneurysms or dissections that were likely to be severe and symptomatic, because these events had prompted admission to hospital or emergency department or had led to death. Thus, aortic aneurysm or dissection diagnosed in outpatient care and registered as a secondary diagnosis in any type of care were not considered to represent outcome events.

Statistical analysis

Patients contributed person time from the date a prescription was filled, to the date of an outcome event, end of follow-up (120 days), end of study period

(31 December 2013), hospital admission, death, or new prescription for a study antibiotic. A single patient could contribute with multiple treatment episodes to the cohort; these episodes were all unique and never overlapped in time, and the outcome event could occur only once in each patient. Hence, assumptions of statistical independence were not violated. Cox proportional hazards regression, with days since start of treatment as the time scale, was used to estimate the hazard ratio for aortic aneurysm or dissection, comparing episodes of fluoroquinolone and amoxicillin use. We assessed the proportional hazards assumption by measuring the interaction between treatment status and time scale using a Wald test.²¹ The absolute rate difference for the 60 day risk period was estimated as (hazard ratio–1)×incidence in the amoxicillin group,²² and reported as the number of cases per million treatment episodes.

We conducted subgroup analyses according to sex and age. In preplanned sensitivity analyses, the outcome definition was varied, assuming that more restrictive definitions might be more specific for the outcome or reflect a more severe disease phenotype. The outcome was restricted to cases of aortic aneurysm or dissection:

- With rupture or dissection alone (not without rupture or dissection)
- Associated with admission to hospital alone (not emergency department) or in which aortic aneurysm or dissection were the underlying cause of death
- Involving patients who had had aortic surgery or died within 30 days of the date of diagnosis or in whom aortic aneurysm or dissection were the underlying cause of death (web table 4).

To assess potential unmeasured confounding, we also analysed the risk of death from any cause; an observed difference in overall mortality between patients treated with fluoroquinolones and amoxicillin would be likely to reflect residual differences in baseline health status or severity of indication (that is, infection) between the groups, rather than a treatment effect. We also conducted a post hoc sensitivity analysis restricted to the first episode included in the study for each individual patient. All analyses were performed using SAS, version 9.4. Results were considered significant when 95% confidence intervals did not overlap 1.0.

Patient involvement

No patients were involved in the development of the research question, the outcome measures, or the design of the study. As a study based on nationwide registers that implement routine registration, no patients were involved in recruitment or conduct of the study, and results will not be disseminated to study participants.

Results

Cohort

Among the source population of 2 333 219 treatment episodes of fluoroquinolone or amoxicillin use, the study eligibility criteria were met for 560 768 episodes of fluoroquinolone use and 440 504 episodes of amoxicillin use (fig 1). After propensity score estimation and 1:1 matching, the study cohort included 720 176 treatment episodes (360 088 in each group). Of the 360 088 episodes of fluoroquinolone

Fig 1 | Nationwide cohort of patients in Sweden with treatment episodes of fluoroquinolone use and amoxicillin use, 2006-13. Values for exclusion criteria do not add up to totals because some episodes were excluded for more than one reason

Table 1 | Baseline characteristics of patients with treatment episodes of oral fluoroquinolone use and amoxicillin use included in 1:1 propensity score matched study cohort. Data are no (%) of patients unless stated otherwise

Characteristic	Oral fluoroquinolones (n=360 088)*	Amoxicillin (n=360 088)†	Standardised difference (%)
Male sex	162 807 (45)	162 641 (45)	0.1
Age (years, mean (standard deviation))	67.9 (10.8)	68.0 (10.4)	0.5
Region of residence			
Stockholm metropolitan area	91 831 (26)	90 777 (25)	0.7
Rest of mid-Sweden	66 294 (18)	66 674 (19)	0.3
Southern Sweden metropolitan areas	60 176 (17)	60 015 (17)	0.1
Rest of southern Sweden	112 523 (31)	113 067 (31)	0.3
Northern Sweden	28 825 (8)	29 122 (8)	0.3
Missing	439 (0.1)	433 (0.1)	0.0
Medical history			
Acute coronary syndrome	13 509 (4)	13 427 (4)	0.1
Other ischaemic heart disease	37 249 (10)	37 077 (10)	0.2
Heart failure or cardiomyopathy	18 877 (5)	19 040 (5)	0.2
Valve disorders	9945 (3)	10 067 (3)	0.2
Cerebrovascular disease	20 388 (6)	20 281 (6)	0.1
Arterial disease	9023 (3)	9002 (3)	0.0
Arrhythmia	37 073 (10)	37 005 (10)	0.1
Cardiac surgery or invasive cardiac procedure in previous year	17 835 (5)	17 817 (5)	0.0
Lung disease	34 688 (10)	34 989 (10)	0.3
Cancer	38 714 (11)	38 234 (11)	0.4
Cancer in previous year	24 491 (7)	24 038 (7)	0.5
Liver disease	3793 (1)	3754 (1)	0.1
Renal disease	9739 (3)	9747 (3)	0.0
Rheumatic disease	16 880 (5)	16 967 (5)	0.1
Psychiatric disorder	22 069 (6)	22 155 (6)	0.1
Prescription drug use in previous year			
Angiotensin converting enzyme inhibitor or angiotensin receptor blocker	117 137 (33)	117 166 (33)	0.0
Calcium channel blocker	63 491 (18)	63 760 (18)	0.2
Loop diuretic	50 204 (14)	50 377 (14)	0.1
Other diuretic	51 656 (14)	51 971 (14)	0.2
β blocker	115 070 (32)	114 998 (32)	0.0
Digoxin	8635 (2)	8794 (2)	0.3
Nitrates	32 136 (9)	32 178 (9)	0.0
Platelet inhibitor	94 148 (26)	94 104 (26)	0.0
Anticoagulant	26 473 (7)	26 730 (7)	0.3
Lipid lowering drug	100 573 (28)	100 584 (28)	0.0
Oral antidiabetic drug	30 529 (9)	30 485 (9)	0.0
Insulin	19 422 (5)	19 308 (5)	0.1
Antidepressant	60 234 (17)	60 524 (17)	0.2
Antipsychotic	8185 (2)	8078 (2)	0.2
Anxiolytic, hypnotic, or sedative drug	110 339 (31)	110 282 (31)	0.0
β2 agonist inhalant	42 946 (12)	43 000 (12)	0.0
Anticholinergic inhalant	19 876 (6)	20 101 (6)	0.3
Glucocorticoid inhalant	56 389 (16)	56 219 (16)	0.1
Oral glucocorticoid	55 767 (16)	55 688 (16)	0.1
Non-steroidal anti-inflammatory drug	104 860 (29)	104 913 (29)	0.0
Opiate	76 958 (21)	77 291 (22)	0.2
Systemic hormone replacement therapy	64 506 (18)	64 474 (18)	0.0
No of drugs used			
1-2	78 004 (22)	78 221 (22)	0.1
3-5	114 617 (32)	114 664 (32)	0.0
6-9	104 278 (29)	104 405 (29)	0.1
≥10	63 189 (18)	62 798 (18)	0.3
Non-study antibiotic in previous 120 days	102 423 (28)	100 711 (28)	1.1
Healthcare use			
Hospital admission due to cardiovascular causes in previous year	16 352 (5)	16 361 (5)	0.0
Hospital admission due to non-cardiovascular causes in previous year	104 353 (29)	104 121 (29)	0.1
Outpatient contact due to cardiovascular causes in previous year	27 862 (8)	27 880 (8)	0.0
Outpatient contact due to non-cardiovascular causes in previous year	191 604 (53)	191 987 (53)	0.2
Emergency department visit in previous 30 days	17 992 (5)	17 534 (5)	0.6

Baseline characteristics of patients before matching are shown in web table 5.

*Total no of patients=282 212.

†Total no of patients=279 337.

use, most were with ciprofloxacin (78%), followed by norfloxacin (20%), and other fluoroquinolones (2%). Baseline characteristics of patients with episodes of fluoroquinolone and amoxicillin use before and after propensity score matching are shown in web table 5 and table 1, respectively. In the matched cohort, all baseline characteristics, as assessed by standardised differences, were well balanced between the groups. The mean follow-up in the 60 day risk period was 52 days (standard deviation 17) days in the fluoroquinolone group and 55 days (14) in the amoxicillin group. The proportional hazards assumption was not violated ($P=0.34$ for primary outcome analysis).

Risk of aortic aneurysm or dissection

In the 60 day risk period, there were 64 cases of aortic aneurysm or dissection among 360 088 treatment episodes of fluoroquinolone use (incidence 1.2 per 1000 person years), compared with 40 cases among 360 088 treatment episodes of amoxicillin use (0.7 per 1000 person years). The cumulative incidence of aortic aneurysm or dissection at 60 days was 2.0×10^{-4} for episodes of fluoroquinolone use and 1.2×10^{-4} for episodes of amoxicillin use (fig 2). There was an increased risk of aortic aneurysm or dissection associated with fluoroquinolone use (hazard ratio 1.66; 95% confidence interval 1.12 to 2.46). This increase corresponded to an absolute difference of 82 (95% confidence interval 15 to 181) cases of aortic aneurysm or dissection per 1 million treatment episodes in the 60 day risk period.

In a secondary analysis, there was no increased risk of aortic aneurysm or dissection associated with fluoroquinolone exposure in the period of 61-120 days from start of treatment (hazard ratio 0.67; 95% confidence interval 0.40 to 1.11). In another secondary analysis, the 60 day risk period was divided into 10 day intervals to explore the timing of the association (table 2). Of 64 cases of aortic aneurysm among patients treated with fluoroquinolones, 26 (41%) occurred in the first 10 days from start of treatment.

In a secondary analysis, the hazard ratio for the association with fluoroquinolone use was 1.90 (95% confidence interval 1.22 to 2.96) for aortic aneurysm

Table 2 | No of events of aortic aneurysm or dissection within the primary 60 day risk period, divided into 10 day intervals since start of treatment with oral fluoroquinolones, compared with amoxicillin*

10 day interval	Oral fluoroquinolones (n=360 088)	Amoxicillin (n=360 088)
1-10	26	9
11-20	9	8
21-30	3	7
31-40	12	6
41-50	6	5
51-60	8	5

*Propensity score matched (1:1 ratio) cohort. Propensity scores were based on 47 covariates including demographic characteristics, medical history, concomitant use of other medical drugs, and measures of healthcare use (that is, baseline characteristics shown in table 1).

and 0.93 (0.38 to 2.29) for aortic dissection (web table 6). Of the cases of aortic aneurysm or dissection that occurred among fluoroquinolone users, most were abdominal aneurysm, followed by thoracic or thoracoabdominal aneurysm (web table 6).

Subgroup and sensitivity analyses

Table 3 shows results of subgroup and sensitivity analyses. In subgroup analyses, the hazard ratios with fluoroquinolone use did not differ significantly between women and men and between subgroups of patients aged 50-64 years and those aged 65 years and above. In sensitivity analyses, the hazard ratios for the association between fluoroquinolone use and aortic aneurysm or dissection were in line with that of the primary analysis when the outcome was restricted to cases:

- With dissection or rupture alone
- Associated with admission to hospital alone (not emergency department) or in which aortic aneurysm or dissection were the underlying cause of death
- Involving patients who had had aortic surgery or died within 30 days of diagnosis or in whom aortic aneurysm or dissection were the underlying cause of death.

The hazard ratio for death from any cause associated with fluoroquinolone use, as compared with amoxicillin, was 1.02 (95% confidence interval 0.97 to 1.08). In a post hoc sensitivity analysis restricted to the first episode included in the study for each individual patient, the hazard ratio for aortic aneurysm or dissection was 1.62 (1.05 to 2.48).

Discussion

Principal findings

In this nationwide, propensity score matched cohort study in Sweden, we investigated the association between use of oral fluoroquinolones and risk of aortic aneurysm or dissection, as compared with use of amoxicillin. Use of fluoroquinolones was associated with a 66% increased rate of aortic aneurysm or dissection within a 60 day risk period from start of treatment, which corresponded to an absolute difference of 82 cases per 1 million treatment episodes.

Fig 2 | Cumulative incidence of aortic aneurysm or dissection within 60 day risk period from start of study treatment

Table 3 | Results of subgroup and sensitivity analyses of the risk of aortic aneurysm or dissection associated with oral fluoroquinolone use as compared with amoxicillin use*

Analysist	Oral fluoroquinolones (n=360 088)		Amoxicillin (n=360 088)		Hazard ratio (95% CI)	P for homogeneity
	No of events	No of events per 1000 person years	No of events	No of events per 1000 person years		
Subgroup analyses‡						
Sex						
Female	23	0.8	11	0.4	2.14 (1.04 to 4.39)	0.41
Male	41	1.8	29	1.2	1.48 (0.92 to 2.39)	
Age						
50-64 years	11	0.5	7	0.3	1.58 (0.61 to 4.07)	0.89
≥65 years	53	1.9	33	1.1	1.70 (1.10 to 2.62)	
Sensitivity analyses, variation of outcome definition						
Cases with dissection or rupture alone	31	0.6	22	0.4	1.45 (0.84 to 2.51)	—
Cases associated with admission to hospital or in which aortic aneurysm or dissection were the underlying cause of death	56	1.1	36	0.7	1.61 (1.06 to 2.45)	—
Cases involving patients who had had aortic surgery or died within 30 days of diagnosis or in whom aortic aneurysm or dissection were the underlying cause of death	43	0.8	29	0.5	1.53 (0.96 to 2.45)	—

*Propensity score matched (1:1 ratio) cohort. Propensity scores were based on 47 covariates including demographic characteristics, medical history, concomitant use of other medical drugs, and measures of healthcare use (that is, baseline characteristics shown in table 1).

†All analyses were conducted for a 60 day risk period following start of treatment.

‡The outcome was defined as admission to hospital or emergency department with an incident diagnosis of aortic aneurysm, with or without rupture, or dissection, or death due to aortic aneurysm or dissection.

Comparison with other studies and interpretation of results

Applying a nationwide design, which ensured generalisability, and methods to attempt to limit the possibility of confounding, our study confirms and substantially expands on the two previous studies that have reported an increased risk of aortic aneurysm or dissection associated with fluoroquinolones. A cohort study among older adults in Ontario, Canada, reported an adjusted hazard ratio of 2.24 (95% confidence interval 2.02 to 2.49) for a risk period of about 37 days.¹² However, that study adjusted for a limited number of covariates and might therefore not have fully accounted for potential confounding due to differences in baseline health status between patients receiving or not receiving fluoroquinolone. Furthermore, it compared fluoroquinolone use with no use of these antibiotics, an analytical design that could have introduced bias because of important unmeasured factors associated with filling an antibiotic prescription. Such factors include infection, which might influence the risk of aortic aneurysm and introduce confounding by indication, and diagnostic assessment (for example, radiological imaging), which might affect the probability of detection of an aneurysm. A nested case-control study from Taiwan used a 60 day risk period and found an adjusted rate ratio of 2.43 (95% confidence interval 1.83 to 3.22)¹¹; likewise, this study did not have an active comparator and could have overestimated the risk.

Our findings suggest that the magnitude of the association between fluoroquinolones and aortic aneurysm, when assessed in a risk period longer than the common duration of a treatment course (usually 7-14 days), might not be as pronounced as indicated by these two previous studies. The studies both

reported more than a twofold increase in risk (although confidence intervals between our and the other studies are overlapping). Our results also indicate that the association could be largely driven by aneurysm, and not dissection.

Furthermore, our study provides some degree of characterisation of the timing of this association, suggesting that the risk associated with fluoroquinolones might be most pronounced in the first 10 days after start of treatment; this would correspond to when treatment is ongoing. If the association is causal, these data indicate that a potential mechanism is relatively acute in onset, largely waning after treatment cessation. Consistent with this finding, the risk of Achilles tendon disorders is highest in the first 15-30 days following start of fluoroquinolone treatment.³ Lending some support to the possibility of a mechanism with acute onset, experimental studies in tendon cells have found that several matrix metalloproteinases, which are known to degrade critical components of the extracellular matrix, are promptly up regulated following exposure to ciprofloxacin.^{5 6} Although a mechanism implicating matrix metalloproteinases has been proposed to be involved in the association between fluoroquinolones and aortic aneurysm,¹¹ and metalloproteinases are known to have a role in the pathophysiology of aortic aneurysm,^{9 10} future experimental work will have to determine how fluoroquinolones interact with the aorta.

Our study supports the notion that fluoroquinolone use could be associated with an increased risk of aortic aneurysm or dissection. Before these results are used to guide clinical decision making, the collective body of data on this safety issue should be scrutinised by drug regulatory authorities and weighed, together with other safety issues with this drug class, against

the benefits of treatment; this will support appropriate clinical treatment recommendations.

Strengths and limitations

An important concern in any observational study is the possibility of confounding. We used an active comparator to limit confounding by factors associated with filling an antibiotic prescription, including confounding by indication, and propensity score matching derived from a range of covariates. Despite this, the possibility of residual confounding (for example, due to differences in smoking status or blood pressure levels between exposure groups) cannot completely be ruled out. Another study limitation, which is generic to database studies, was our reliance on filled prescriptions to define drug exposure; non-adherence to fluoroquinolones would bias results towards the null.

The possibility of protopathic bias cannot be excluded—whereby initial symptoms of aortic aneurysm are clinically interpreted as possible infection and lead to fluoroquinolone treatment, which would result in overestimation of risk. However, protopathic bias seems unlikely because infection is not a common first diagnosis in cases where aortic aneurysm is initially misdiagnosed. In a systematic review based on eight studies and 927 patients, among patients in whom ruptured abdominal aortic aneurysm was initially misdiagnosed, the most common initial diagnoses were renal colic (6% of total patients), myocardial infarction (6%), colonic inflammation (3%), and gastrointestinal perforation (3%), whereas 12% did not receive an initial diagnosis.²³ On a similar note, if an infection represented indication for treatment with fluoroquinolones, but not amoxicillin, and later led to development of an infectious aneurysm, it would bias results towards increased risk.^{24–25} This possibility too appears unlikely to explain the observed results because infected aneurysms are rare, representing 0.5–2.5% of all aortic aneurysms, and because patients with infected aneurysm may present without a preceding infectious episode. Most treatment episodes with fluoroquinolones in our study were with ciprofloxacin and results are therefore mainly applicable to this specific fluoroquinolone. Additional studies are needed to investigate whether there are differences between individual fluoroquinolones with respect to the risk of aortic aneurysm. Further work is also needed to confirm that the association is driven by aortic aneurysm, and not dissection, as well as the timing of onset of aortic aneurysm suggested by our study.

Contributors: BP had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. All authors conceived and designed the study; acquired, analysed, and interpreted the data; and critically revised the manuscript for important intellectual content. BP drafted the manuscript. HS carried out the statistical analysis. All authors obtained funding. BP and HS are the guarantors.

Funding: There was no specific funding for this study. BP is supported by an investigator grant from the Strategic Research Area Epidemiology programme at Karolinska Institutet. MI is supported by an investigator grant from the Swedish Government Funds for

Clinical Research (ALF). HS is supported by an investigator grant from the Lundbeck Foundation. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: The study was approved by the Regional Ethics Committee in Lund, Sweden (2013/717).

Data sharing: No additional data available. Statistical code available on request.

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

- Hicks LA, Taylor TH Jr, Hunkler RJUS. US outpatient antibiotic prescribing, 2010. *N Engl J Med* 2013;368:1461–2. 10.1056/NEJMc1212055
- Hicks LA, Bartoces MG, Roberts RM, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. *Clin Infect Dis* 2015;60:1308–16.
- Stephenson AL, Wu W, Cortes D, Rochon PA. Tendon injury and fluoroquinolone use: a systematic review. *Drug Saf* 2013;36:709–21. 10.1007/s40264-013-0089-8
- Cipro (ciprofloxacin product information). Bayer HealthCare. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019537s085,020780s042lbl.pdf.
- Tsai WC, Hsu CC, Chen CP, et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. *J Orthop Res* 2011;29:67–73. 10.1002/jor.21196
- Corps AN, Harrall RL, Curry VA, Fenwick SA, Hazleman BL, Riley GP. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1beta in human tendon-derived cells. A potential mechanism of fluoroquinolone-induced tendinopathy. *Arthritis Rheum* 2002;46:3034–40. 10.1002/art.10617
- Chang HN, Pang JH, Chen CP, et al. The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin. *J Orthop Res* 2012;30:764–8. 10.1002/jor.21576
- Pouzaud F, Bernard-Beauvois K, Thevenin M, Warnet JM, Hayem G, Rat P. In vitro discrimination of fluoroquinolones toxicity on tendon cells: involvement of oxidative stress. *J Pharmacol Exp Ther* 2004;308:394–402. 10.1124/jpet.103.057984
- Kent KC. Clinical practice. Abdominal aortic aneurysms. *N Engl J Med* 2014;371:2101–8. 10.1056/NEJMc1401430
- Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic aneurysm and dissection. *J Am Coll Cardiol* 2014;64:1725–39. 10.1016/j.jacc.2014.08.025
- Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. *JAMA Intern Med* 2015;175:1839–47. 10.1001/jamainternmed.2015.5389
- Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. *BMJ Open* 2015;5:e010077. 10.1136/bmjopen-2015-010077
- Fluoroquinolones. Signal of aortic aneurysm and dissection. Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of PRAC meeting on 10–13 May 2016. www.ema.europa.eu/docs/en_GB/document_library/Minutes/2016/07/WC500209623.pdf.
- Wettermark B, Hammar N, Forel CM, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months [correction in: *Pharmacoepidemiol Drug Saf* 2008;17:533]. *Pharmacoepidemiol Drug Saf* 2007;16:726–35. 10.1002/pds.1294
- National Patient Register. National Board of Health and Welfare. www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish.
- Parson LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference, 2001. Paper 214–26. www2.sas.com/proceedings/sugi26/p214-26.pdf.

- 17 Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. *Circ Cardiovasc Qual Outcomes* 2008;1:62-7. 10.1161/CIRCOUTCOMES.108.790634
- 18 D'Agostino RB Jr, Rubin DB. Estimating and using propensity scores with partially missing data. *J Am Stat Assoc* 2000;95:749-59. 10.1080/01621459.2000.10474263.
- 19 Landenhed M, Engström G, Gottsäter A, et al. Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study. *J Am Heart Assoc* 2015;4:e001513. 10.1161/JAHA.114.001513
- 20 Sundbøll J, Adelborg K, Munch T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. *BMJ Open* 2016;6:e012832. 10.1136/bmjopen-2016-012832
- 21 Collett D. *Modelling survival data in medical research*. Chapman & Hall/CRC, 2003.
- 22 Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. *N Engl J Med* 2013;368:1704-12. 10.1056/NEJMoa1300799
- 23 Azhar B, Patel SR, Holt PJ, Hinchliffe RJ, Thompson MM, Karthikesalingam A. Misdiagnosis of ruptured abdominal aortic aneurysm: systematic review and meta-analysis. *J Endovasc Ther* 2014;21:568-75. 10.1583/13-4626MR.1
- 24 Sörelus K, Mani K, Björck M, et al, European MAA collaborators. Endovascular treatment of mycotic aortic aneurysms: a European multicenter study. *Circulation* 2014;130:2136-42. 10.1161/CIRCULATIONAHA.114.009481
- 25 Laohapensang K, Rutherford RB, Arworn S. Infected aneurysm. *Ann Vasc Dis* 2010;3:16-23. 10.3400/avd.ctiia09002

Web appendix: Supplementary material